2247995-37-3 Lanzetinib Mesylate

Application:

     Lanzetinib mesylate is mainly used to treat non-small cell lung cancer (NSCLC) patients carrying specific epidermal growth factor receptor (EGFR) gene mutations. This drug targets and inhibits EGFR mutant proteins (such as T790M mutation), blocking tumor cell growth signals and delaying disease progression.

Synonyms:

Lazertinib mesylate anhydrous

2-Propenamide, N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenyl-1H-pyrazol-1-yl]-2-pyrimidinyl]amino]-4-methoxy-2-(4-morpholinyl)phenyl]-, methanesulfonate (1:1)

2247995-37-3

Hot Tags: 2247995-37-3 lanzetinib mesylate, China 2247995-37-3 lanzetinib mesylate manufacturers, suppliers, Dibenzoyl D tartaric acid, Ivacaftor VX 770 , Nelarabine, D Lysergic Acid Methyl Ester, Loratadine, C62H86N12O16